BioCentury | Apr 29, 2020
Distillery Therapeutics

Inhibiting endocytosis to enhance cetuximab, trastuzumab and Bavencio antitumor efficacy Bavencio to treat first-line renal cell carcinoma, Merkel cell carcinoma and urothelial cancer. TARGET/MARKER/PATHWAY: Dynamin (DMN)...
BioCentury | May 21, 2015
Distillery Therapeutics

Therapeutics: Dynamin (DMN)

...or no treatment. Next steps could include optimizing the small molecule for clinical testing. TARGET/MARKER/PATHWAY: Dynamin (DMN)...
BioCentury | Sep 8, 2011
Distillery Therapeutics

Indication: Infectious disease

...Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Clostridium Dynamin (DMN) Mouse and cell...
Items per page:
1 - 3 of 3